Clinical Study

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy

Table 2

Detailed descriptive results on plasma levels of the selected inflammatory molecules for all measurement points.

pg/ml or ng/ml^MeanSDMedianMinimumMaximum75th perc25th perc

CCL2 baseline131.532.1127.466.7203.3110.0139.8
CCL2 8 Gy136.837.7134.660.5200.4111.9171.4
CCL2 50 Gy146.641.8145.857.7217.1118.6167.1
CCL2 end RT157.334.5158.4102.6240.8131.2174.1
CCL2 1 mos167.979.7143.274.6461.7127.5187.2

IL-1b baseline0.00.00.00.00.20.00.0
IL-1b 8 Gy0.00.10.00.00.50.00.0
IL-1b 50 Gy0.00.00.00.00.00.00.0
IL-1b end RT0.00.00.00.00.00.00.0
IL-1b 1 mos0.00.00.00.00.20.00.0

IL-6 baseline1.61.21.60.03.50.32.5
IL-6 8 Gy1.41.32.10.03.20.22.3
IL-6 50 Gy1.61.41.60.04.70.22.3
IL-6 end RT1.61.11.80.03.21.32.3
IL-6 1 mos1.71.22.20.03.90.52.5

CXCL8 baseline5.72.05.23.710.44.35.9
CXCL8 8 Gy5.52.44.63.412.53.96.4
CXCL8 50 Gy5.72.05.13.711.44.46.2
CXCL8 end RT6.32.75.42.913.44.67.7
CXCL8 1 mos8.39.15.74.146.14.77.2

PTX3 baseline3.31.13.01.85.62.34.3
PTX3 8 Gy3.91.23.91.96.33.14.6
PTX3 50 Gy3.31.13.31.65.62.54.0
PTX3 end RT3.51.33.71.46.32.64.1
PTX3 1 mos3.11.13.11.15.12.04.0

TNF alpha baseline3.12.53.90.07.40.44.9
TNF alpha 8 Gy2.72.32.90.06.50.44.9
TNF alpha 50 Gy2.82.62.70.09.20.24.6
TNF alpha end RT2.72.22.80.06.10.24.5
TNF alpha 1 mos3.12.23.60.07.01.24.3

^pg/ml for IL-1b, IL-6, CXCL8, CCL2, and TNF alpha; ng/ml: PTX3; SD: standard deviation; perc: percentile; 1 mos: 1 month; RT: radiotherapy.